Long COVID and the peptide research landscape — what's been explored

This is long COVID — and naming it doesn't resolve the most important question, which is what's actually happening in the body, and why it persists in some people and not others.

The conventional medicine response to long COVID has been largely supportive. Rest. Pacing. Symptomatic management — beta-blockers for the heart rate dysregulation, antihistamines for the mast-cell-like flares, sleep hygiene for the sleep that doesn't restore, gradual reconditioning programs for the exercise intolerance that has to be approached with extraordinary care because pushing through it makes things worse, not better. The workup for most long COVID patients comes back unremarkable: normal inflammatory markers, normal cardiac function on basic imaging, normal thyroid, normal metabolic panel. The lab results and the lived experience occupy completely different realities.

That gap — between normal labs and a body that clearly isn't functioning normally — is the central problem. It's also what has driven a parallel research conversation that runs alongside mainstream medicine and intersects with it imperfectly: what if some of what's happening in long COVID responds to mechanisms that standard pharmacology isn't targeting?

Here is what the research and clinical hypothesis landscape looks like, with honest caveats about what each part of it actually shows.

The biology of long COVID is still being actively characterized, which is part of why it's so difficult to treat. Several overlapping mechanisms appear to be operating simultaneously, and they may operate differently in different patients. There's evidence of viral persistence — fragments of SARS-CoV-2 in gut tissue, in lymph nodes, in other reservoirs, continuing to drive immune activation long after the acute phase resolves. There's evidence of mitochondrial dysfunction: impaired energy production at the cellular level that may explain the fatigue and the post-exertional malaise in ways that don't show up on standard panels. There's autonomic nervous system dysregulation — disrupted signaling between the brain and peripheral systems that governs heart rate, blood pressure, digestion, and basic physiological homeostasis. In a substantial subset of patients, there appears to be mast cell hyperactivation — an immune-cell population that when dysregulated produces a pattern of histamine-like reactions, neurological symptoms, and systemic flares that doesn't fit classic allergy but doesn't fit classic autoimmunity either.

All of these threads open onto different potential interventions, and none of them has a clean pharmacological answer yet.

The peptide research conversation in long COVID is primarily observational and clinician-network-driven. There are no large randomized controlled trials of peptides in long COVID as of this writing. What exists is a combination of mechanistic reasoning from other research contexts, case series from clinicians treating long COVID patients in functional and integrative medicine settings, and small studies investigating peptides for the specific physiological problems — immune dysregulation, mitochondrial dysfunction, autonomic disruption — that long COVID appears to involve. That distinction matters. Observational data and mechanistic plausibility are not the same as controlled trial evidence, and anyone presenting peptide approaches for long COVID as established treatment is overstating the literature.

With that framing established: here is what has been explored.

Vasoactive intestinal peptide, known as VIP, is a neuropeptide with a wide range of functions — anti-inflammatory, vasodilatory, neuromodulatory, and involved in regulating immune balance between inflammatory and tolerogenic states. VIP receptors are found in the lung, gut, brain, and immune tissue. Researcher and clinician Dr. Michael Ruscio and others in the functional medicine space have written about VIP's potential relevance to long COVID, particularly for patients with pulmonary symptoms, autonomic dysfunction, and inflammatory dysregulation. Separately, Dr. Ritchie Shoemaker's work on biotoxin illness and chronic inflammatory response syndrome explored intranasal VIP as part of a multi-step protocol — research that preceded long COVID but shares substantial mechanistic overlap. VIP is not FDA-approved for long COVID. It is a compounded peptide with a mechanism that is biologically plausible for several of the pathways implicated in long COVID, and some clinicians have incorporated it into post-COVID protocols. The evidence is preliminary.

Thymosin Alpha-1 is a peptide derived from thymosin fraction 5, isolated from thymus tissue. It is FDA-approved in over thirty countries for viral hepatitis and as an immune adjuvant for certain cancers, though it does not have FDA approval in the United States. Its primary mechanism is immune normalization — supporting regulatory T-cell function, modulating innate and adaptive immunity, and reducing chronic immune activation. The hypothesis for its relevance to long COVID involves the evidence for ongoing immune dysregulation in some patients: abnormal T-cell populations, elevated cytokines, and patterns that suggest immune exhaustion or dysregulation rather than resolution. Thymosin Alpha-1 has been used in clinical contexts for chronic viral infections including HIV and hepatitis, and some clinicians working with long COVID have incorporated it on the basis of this prior use. The evidence is more developed than for many other peptides, though it still lacks long-COVID-specific RCT data.

BPC-157 — body protection compound 157 — is a synthetic peptide derived from a protective protein found in gastric juice. The research base for BPC-157 is primarily preclinical (animal studies), with some human observational data in the context of gut healing and musculoskeletal repair. Its relevance to long COVID is hypothesized through multiple channels: the gut-brain axis disruption that many long COVID patients experience, the systemic inflammation that appears to underlie many symptoms, and the potential for gut microbiome restoration as part of recovery. The evidence for BPC-157 in long COVID specifically is largely theoretical, derived from extrapolation of its mechanisms in other contexts. Clinicians using it in post-COVID protocols are doing so on the basis of plausible mechanism and observed outcomes in patients, not controlled trial data.

The mitochondrial angle in long COVID has attracted significant research attention. Post-COVID energy dysregulation has markers that look like mitochondrial dysfunction — impaired oxidative phosphorylation, abnormal lactate metabolism after exercise, patterns on muscle biopsy in some patients that suggest mitochondrial-level disruption. This has directed interest toward compounds that support mitochondrial function: NAD+ precursors (nicotinamide riboside, NMN) for supporting the NAD/NADH balance that mitochondrial energy production depends on; MOTS-c, a mitochondria-derived peptide that influences metabolic regulation and insulin sensitivity; and SS-31 (elamipretide), a peptide that appears to target the inner mitochondrial membrane and support its structural integrity. SS-31 is under active investigation in clinical trials for heart failure and other conditions; its long-COVID relevance is primarily mechanistic. MOTS-c research is largely preclinical. NAD+ support has the most accessible evidence base and the broadest clinical use, though controlled trial evidence in long COVID remains limited.

Low-dose naltrexone — often abbreviated LDN — sits adjacent to the peptide conversation. Naltrexone is FDA-approved at standard doses for opioid and alcohol use disorder. At very low doses (1.5 to 4.5 mg), taken at night, it appears to have anti-inflammatory and immune-modulating effects that are distinct from its opioid-antagonist mechanism — likely mediated through toll-like receptor 4 and microglial modulation. LDN is not FDA-approved for long COVID, but it has been the subject of small trials in fibromyalgia, inflammatory bowel disease, and multiple sclerosis, and it has an active and growing prescribing community in post-COVID contexts. Its safety profile is favorable compared to most other interventions in this space. It represents one of the more studied off-label options, with the caveat that "more studied" in this context still means the evidence is preliminary.

The intersection between long COVID and mast cell activation syndrome deserves particular attention, because the two conditions share enough features that some researchers have questioned whether they're separable. Mast cells are immune cells present in virtually every tissue; when dysregulated, they release histamine and a broad range of inflammatory mediators in patterns that can produce systemic symptoms — flushing, fatigue, cognitive dysfunction, GI disruption, neurological symptoms — in the absence of findings on standard allergy testing. A substantial fraction of long COVID patients have mast-cell-like presentations, and a substantial fraction of known MCAS patients reported worsening or new-onset symptoms after COVID infection. Whether SARS-CoV-2 is triggering MCAS in susceptible individuals, or whether long COVID activates a similar but distinct mast-cell pathway, is still being worked out. The treatment implications overlap: antihistamines, mast cell stabilizers, VIP, and low-histamine dietary approaches all appear in both MCAS and long COVID management protocols.

None of this replaces what remains foundational. Pacing — the practice of staying deliberately below the threshold that triggers post-exertional malaise — is the most evidence-supported intervention in long COVID and ME/CFS, the condition it most resembles. This is counterintuitive for people who have spent their lives being told to push through fatigue. In post-exertional malaise, pushing through isn't grit. It's pathophysiology working against itself. Sleep optimization matters — not because sleep fixes long COVID, but because sleep deprivation compounds every other dysfunction at play. Autonomic rehabilitation, conducted carefully and monitored for tolerance, helps some patients. Addressing comorbidities — sleep apnea, nutritional deficiencies, gut dysbiosis — removes variables that make recovery harder.

The honest picture of where peptide research fits into long COVID treatment is this: there are mechanistically plausible compounds that may help support some of the specific physiological disruptions underlying the condition. None of them is a cure. None of them has been validated in large, well-designed long-COVID-specific clinical trials. The evidence base is preliminary, clinician-driven, and improving slowly. The research community is still characterizing the condition itself well enough to design trials.

What this means practically is that peptide approaches to long COVID require specialist evaluation — not a general practitioner who may not be familiar with the relevant literature, but a clinician with specific experience in post-COVID care, ideally through one of the post-COVID specialty clinics that have emerged at academic medical centers, or through a provider experienced in the functional and integrative medicine overlap with this condition. These clinicians can do the workup that actually differentiates between the subtypes of long COVID — autonomic predominant, immune predominant, mast-cell predominant, mitochondrial — and can calibrate interventions accordingly. The pattern of your symptoms matters. The mechanisms underlying your particular presentation matter. Treatment approached without that differentiation is guesswork, and in a condition where the wrong intervention can trigger crashes, guesswork has a cost.

Long COVID is not a mystery in the sense that nothing is known about it. It is a mystery in the sense that what's known is fragmented, contested, and not yet organized into a treatment framework that conventional medicine can fully endorse. The research is moving. Specialist evaluation is the entry point into whatever the current best version of that care looks like.